January 16, 2020     Apremilast Continues to Show Viability as Monotherapy Psoriatic arthritis patients with moderate disease activity were more likely to reach treatment targets or low disease activity at week 52 with apremilast (Otezla, Celgene) than patients with high disease activity, researchers report in the January 7 issue of Arthritis Care and Research. Learn more   ADVERTISEMENT Risk of Infection in Psoriasis Lower with Some Biologics Psoriasis patients have a lower risk of serious infection with specific biologic and non-biologic medications than with methotrexate, based on new research results. Learn more in this slideshow   RHEUMATOLOGY HEALTHCARE JOB OPPORTUNITIES Visit Rheumatology Network for easy access to new job opportunities in rheumatology. As a service to our readers, we've posted a national "Job Board" in the upper right-hand corner of the site. Suggestions for other content sections? Email the editor at areyes@mmhgroup.com.